R. G. Niederhoffer Capital Management Inc. decreased its holdings in Celgene Co. (NASDAQ:CELG) by 50.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,000 shares of the biopharmaceutical company’s stock after selling 3,100 shares during the quarter. Celgene comprises about 2.8% of R. G. Niederhoffer Capital Management Inc.’s portfolio, making the stock its 17th biggest position. R. G. Niederhoffer Capital Management Inc.’s holdings in Celgene were worth $437,000 at the end of the most recent quarter.
Several other institutional investors have also bought and sold shares of CELG. Thompson Davis & CO. Inc. lifted its position in Celgene by 5.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 43 shares during the period. Arcadia Investment Management Corp MI lifted its position in Celgene by 118.7% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 400 shares during the period. Guidant Wealth Advisors acquired a new stake in Celgene during the 3rd quarter worth about $119,000. Motco lifted its position in Celgene by 19.3% during the 2nd quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after acquiring an additional 159 shares during the period. Finally, Penserra Capital Management LLC acquired a new stake in Celgene during the 2nd quarter worth about $129,000. 79.74% of the stock is owned by hedge funds and other institutional investors.
Celgene Co. (NASDAQ:CELG) opened at $105.49 on Wednesday. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31. Celgene Co. has a 52 week low of $94.55 and a 52 week high of $147.17. The firm has a market capitalization of $83,050.00, a PE ratio of 24.88, a P/E/G ratio of 0.68 and a beta of 1.77.
A number of brokerages have commented on CELG. Zacks Investment Research raised Celgene from a “sell” rating to a “hold” rating in a research report on Monday. SunTrust Banks set a $127.00 price target on Celgene and gave the stock a “buy” rating in a research report on Monday. Credit Suisse Group set a $125.00 price target on Celgene and gave the stock a “buy” rating in a research report on Monday. Stifel Nicolaus set a $130.00 price objective on Celgene and gave the company a “buy” rating in a report on Monday. Finally, Deutsche Bank set a $110.00 price objective on Celgene and gave the company a “hold” rating in a report on Monday. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and nineteen have assigned a buy rating to the company. Celgene has an average rating of “Buy” and a consensus price target of $131.35.
ILLEGAL ACTIVITY WARNING: This report was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.com-unik.info/2018/01/10/celgene-co-celg-stake-decreased-by-r-g-niederhoffer-capital-management-inc.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.